A Drug Lag Update

Wardell WM . Introduction of new therapeutic drugs in the United States and Great Britain: an international comparison. Clin Pharmacol Ther. 1973;14(5):773–790.

Wardell WM . The drug lag revisited: comparison by therapeutic area of patterns of drugs marketed in the United States and Great Britain from 1972 through 1976. Clin Pharmacol Ther. 1978;24(5):499–524.

Wardell WM . Therapeutic implication of the drug lag. Clin Pharmacol Ther. 1974;15(1):73–96.

Wardell WM . Statement at hearing on the Food and Drug Administration's new drug approval process, before the Subcommittee on Science, Research, and Technology of the Committee on Science and Technology, US House of Representatives, June 19, 1979. Washington, DC: US GPO, 1979.

Kennedy D. A calm look at “drug lag.” JAMA. 1978;239(5):423–426.

Kennedy D. Statement at hearing on the Food and Drug Administration's new drug approval process, before the Subcommittee on Science, Research, and Technology of the Committee on Science and Technology, US House of Representatives, June 21, 1979. Washington, DC: US GPO, 1979.

Kaitin KI Mattison N Northington FK Lasagna L. The drug lag: an update of new drug introductions in the United States and the United Kingdom, 1977 through 1987. Clin Pharmacol Ther. 1989;46(2):121–138.

Kaitin KI Richard BW Lasagna L. Trends in drug development: the 1985-86 new drug approvals. J Clin Pharmacol. 1987;27(8):542–548.

Kaitin KI DiCerbo PA Lasagna L. The new drug approvals of 1987, 1988, and 1989: trends in drug development. J Clin Pharmacol. 1991;31(2):116–122.

Kaitin KI Manocchia M Seibring M Lasagna L. The new drug approvals of 1990, 1991, and 1992: trends in drug development. J Clin Pharmacol. 1994;34(2):120–127.

Cullen R. Pharmaceuticals inter-country diffusion. Managerial Decision Econ. 1983;4(2):73–82.

Hass AE Jr. Where drug marketing patterns are similar. Med Mark Media. 1983;18:78–83.

Wittes RE . Antineoplastic agents and FDA regulations: square pegs for round holes? Cancer Treat Rep. 1987;71(9):795–806.

Bienz-Tadmor B. Biopharmaceuticals go to market: patterns of worldwide development. Biol Technology. 1993;11(2):168–172.

Bienz-Tadmor B Brown JS Seo PS Bryant NR . Availability of biopharmaceuticals and conventional drugs in the United States, Europe, and Japan. Presented at the 94th Annual Meeting of the American Society of Clinical Pharmacology and Therapeutics, March 1993, Honolulu.

Bienz-Tadmor B Brown J. Biopharmaceuticals and conventional drugs: comparing development times. BioPharm. 1994;7(2):44–49.

Vinar O Klein DF Potter WZ Gause EM . A survey of psychotropic medications not available in the United States. Neuropsychopharmacol. 1991;5(4):201–217.

The NDA Pipeline-1993. Chevy Chase, MD: F-D-C Development Corp., 1994.

DiMasi JA Lasagna L. The economics of psychotropic drug development. Chapter 160 in Psychopharmacology: the fourth generation of progress. Bloom FE Kupfer DJ eds. New York: Raven Press; 1995:1883–1896.

Kessler DA . FDA and America's competitiveness. Distinguished Speaker address at the 1992 Harold and Jane Hirsh Health Policy Symposium, George Washington University, June 22, 1992.

Bakke OM Wardell WM Lasagna L. Drug discontinuations in the United Kingdom and the United States, 1964 to 1983: issues of safety. Clin Pharmacol Ther. 1984;35(5):559–567.

Bakke OM Manocchia M deAbajo F Kaitin KI Lasagna L. Drug Safety Discontinuations in the UK, the US, and Spain, 1974-1993: A Regulatory Perspective. Clin Pharmacol Ther. 1995;57.

Competitive Enterprise Institute. Consumer advocacy group attacks FDA for slow approval of cancer treatment. Kazman S. May 14, 1992, press release.

First do no harm. Wall Street Journal. Dec. 21, 1987:20.